CA3087838A1 - Minocycline for treating inflammatory skin conditions - Google Patents
Minocycline for treating inflammatory skin conditions Download PDFInfo
- Publication number
- CA3087838A1 CA3087838A1 CA3087838A CA3087838A CA3087838A1 CA 3087838 A1 CA3087838 A1 CA 3087838A1 CA 3087838 A CA3087838 A CA 3087838A CA 3087838 A CA3087838 A CA 3087838A CA 3087838 A1 CA3087838 A1 CA 3087838A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- doxycycline
- minocycline
- rosacea
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741023993 | 2018-01-07 | ||
| IN201741023993 | 2018-01-07 | ||
| PCT/IB2019/000144 WO2019135166A1 (en) | 2018-01-07 | 2019-01-07 | Minocycline for treating inflammatory skin conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3087838A1 true CA3087838A1 (en) | 2019-07-11 |
Family
ID=65269058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3087838A Pending CA3087838A1 (en) | 2018-01-07 | 2019-01-07 | Minocycline for treating inflammatory skin conditions |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11191740B2 (https=) |
| EP (1) | EP3735249A1 (https=) |
| JP (3) | JP7561029B2 (https=) |
| KR (1) | KR102705507B1 (https=) |
| CN (1) | CN111818927A (https=) |
| AU (2) | AU2019205134B9 (https=) |
| BR (1) | BR112020013789A2 (https=) |
| CA (1) | CA3087838A1 (https=) |
| EA (1) | EA202091653A1 (https=) |
| MX (1) | MX2020007222A (https=) |
| WO (1) | WO2019135166A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7561029B2 (ja) | 2018-01-07 | 2024-10-03 | ドクター レディズ ラボラトリーズ リミテッド | 炎症性皮膚状態を処置するためのミノサイクリン |
| CA3106884C (en) * | 2018-07-19 | 2025-04-01 | Doosan Bobcat North America, Inc. | DISPLAY POSITION FOR CABIN WITH TILTING DOOR |
| CN120324439A (zh) * | 2025-03-05 | 2025-07-18 | 福安药业集团宁波天衡制药有限公司 | 一种稳定的盐酸米诺环素胶囊及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1383508B1 (en) * | 2001-04-05 | 2006-06-21 | Collagenex Pharmaceuticals, Inc. | Doxycycline for the treatment of acne |
| US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| EP1494681A4 (en) * | 2002-04-16 | 2008-08-06 | Collagenex Pharm Inc | PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA |
| US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20080242642A1 (en) | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20140186269A1 (en) | 2013-01-03 | 2014-07-03 | Foamix Ltd. | Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders |
| US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| PT106679B (pt) | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | Formulações tópicas de tetraciclinas, sua preparação e usos |
| JP7561029B2 (ja) | 2018-01-07 | 2024-10-03 | ドクター レディズ ラボラトリーズ リミテッド | 炎症性皮膚状態を処置するためのミノサイクリン |
-
2019
- 2019-01-07 JP JP2020537525A patent/JP7561029B2/ja active Active
- 2019-01-07 AU AU2019205134A patent/AU2019205134B9/en active Active
- 2019-01-07 CA CA3087838A patent/CA3087838A1/en active Pending
- 2019-01-07 BR BR112020013789-8A patent/BR112020013789A2/pt not_active Application Discontinuation
- 2019-01-07 MX MX2020007222A patent/MX2020007222A/es unknown
- 2019-01-07 WO PCT/IB2019/000144 patent/WO2019135166A1/en not_active Ceased
- 2019-01-07 CN CN201980017148.7A patent/CN111818927A/zh active Pending
- 2019-01-07 KR KR1020207022760A patent/KR102705507B1/ko active Active
- 2019-01-07 EP EP19714476.9A patent/EP3735249A1/en active Pending
- 2019-01-07 US US16/241,754 patent/US11191740B2/en active Active
- 2019-01-07 EA EA202091653A patent/EA202091653A1/ru unknown
-
2020
- 2020-03-23 US US16/827,622 patent/US10905664B2/en active Active
- 2020-12-23 US US17/132,825 patent/US11364212B2/en active Active
-
2022
- 2022-06-20 US US17/844,715 patent/US12594252B2/en active Active
-
2024
- 2024-05-15 JP JP2024079573A patent/JP2024098011A/ja active Pending
-
2025
- 2025-02-06 AU AU2025200826A patent/AU2025200826A1/en active Pending
- 2025-12-02 JP JP2025219443A patent/JP2026031656A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091653A1 (ru) | 2020-12-23 |
| KR102705507B1 (ko) | 2024-09-10 |
| WO2019135166A9 (en) | 2020-07-16 |
| AU2019205134A1 (en) | 2020-08-20 |
| US10905664B2 (en) | 2021-02-02 |
| AU2019205134B2 (en) | 2024-11-07 |
| RU2020125984A3 (https=) | 2022-02-07 |
| US12594252B2 (en) | 2026-04-07 |
| KR20200108018A (ko) | 2020-09-16 |
| BR112020013789A2 (pt) | 2021-02-17 |
| JP2026031656A (ja) | 2026-02-24 |
| JP2021509409A (ja) | 2021-03-25 |
| US20200222345A1 (en) | 2020-07-16 |
| RU2020125984A (ru) | 2022-02-07 |
| AU2019205134A2 (en) | 2020-08-20 |
| EP3735249A1 (en) | 2020-11-11 |
| US11191740B2 (en) | 2021-12-07 |
| AU2019205134B9 (en) | 2025-02-20 |
| JP7561029B2 (ja) | 2024-10-03 |
| JP2024098011A (ja) | 2024-07-19 |
| US20190209500A1 (en) | 2019-07-11 |
| WO2019135166A1 (en) | 2019-07-11 |
| CN111818927A (zh) | 2020-10-23 |
| US20210121420A1 (en) | 2021-04-29 |
| MX2020007222A (es) | 2020-12-10 |
| US11364212B2 (en) | 2022-06-21 |
| AU2025200826A1 (en) | 2025-02-27 |
| US20230131030A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12594252B2 (en) | Methods for treating inflammatory skin conditions | |
| WO2009034541A2 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
| KR20210147082A (ko) | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 | |
| WO2018108152A1 (zh) | 一种奥拉帕尼口服缓控释药物组合物及其用途 | |
| JP2012506911A (ja) | ジアセレインを含有する医薬組成物 | |
| CN102348455A (zh) | 药物剂型的活性包衣 | |
| JP7592001B2 (ja) | エフロルニチンとスリンダクの固定用量複合製剤 | |
| EP2533767A1 (en) | Pharmaceutical compositions comprising a combination of metformin and sitagliptin | |
| WO2018108157A1 (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| RU2787528C2 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| WO2015063670A1 (en) | Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof | |
| EA045615B1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| HK40039196A (en) | Minocycline for treating inflammatory skin conditions | |
| US20130209553A1 (en) | Extended release pharmaceutical compositions of pramipexole | |
| TWI743059B (zh) | 二氟甲基鳥氨酸及舒林酸(sulindac),固定劑量組合調配物 | |
| WO2016162754A1 (en) | Pharmaceutical compositions for minocycline | |
| KR20130094117A (ko) | 록소프로펜 방출제어형 제제 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231222 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250103 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250103 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250103 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250228 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250617 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250617 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250618 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250623 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250709 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260102 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260102 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260401 |